Moderna shares fell 3% Thursday afternoon, after reports that federal health officials are re-evaluating the company’s $590 million contract to help develop a bird-flu vaccine. Moderna was awarded the ...

Moderna (NASDAQ: MRNA) became a hot investment during the pandemic as its COVID vaccine made investors bullish on its future.

We expect Moderna MRNA to surpass expectations when ... generated a major portion of its revenues from selling its COVID-19 vaccine. Our model estimate for the vaccine’s sales is pegged at ...

The softer sales expectation is likely due to the vaccine being approved and recommended later in the contracting season. By that time, many customers must have already completed their orders. Moderna ...

U.S. President Donald Trump claimed on Tuesday that U.S. banks are not allowed to do business in Canada, while their banks ...

Moderna's COVID sales have been declining ... and definitively improve its top line. The one wild card is the personalized cancer vaccine it is developing with Merck. But that's not guaranteed ...

The Trump administration is reconsidering a $590 million human bird flu vaccine contract with Moderna. ( The Hill) Over 40% ...

The facility is the centrepiece of a 10-year agreement-in-principle between the biotech and the UK government – which has been rumoured to be on the cards ... of Moderna’s COVID-19 vaccine ...